Abstract:Metal-based complexes have occupied a pioneering niche in the treatment of many chronic diseases, including various types of cancers. Despite the phenomenal success of cisplatin for the treatment of many solid malignancies, a limited number of metallo-drugs are in clinical use against cancer chemotherapy till date. While many other prominent platinum and non‑platinum- based metallo-drugs (e.g. NAMI-A, KP1019, carboplatin, oxaliplatin, titanocene dichloride, casiopeinas® etc) have entered clinical trials, many have failed at later stages of R&D due to deleterious toxic effects, intrinsic resistance and poor pharmacokinetic response and low therapeutic efficacy. Nonetheless, research in the area of medicinal inorganic chemistry has been increasing exponentially over the years, employing novel target based drug design strategies aimed at improving pharmacological outcomes and at the same time mitigating the side-effects of these drug entities. Over the last few decades, natural products became one of the key structural motifs in the anticancer drug development. Many eminent researchers in the area of medicinal chemistry are devoted to develop new 3d-transition metal-based anticancer drugs/repurpose the existing bioactive compounds derived from myriad pharmacophores such as coumarins, flavonoids, chromones, alkaloids etc. Metal complexes of natural alkaloids and their analogs such as luotonin A, jatrorrhizine, berberine, oxoaporphine, 8-oxychinoline etc. have gained prominence in the anticancer drug development process as the naturally occurring alkaloids can be anti-proliferative, induce apoptosis and exhibit inhibition of angiogenesis with better healing effect. While some of them are inhibitors of ERK signal-regulated kinases, others show activity based on cyclooxygenases-2 (COX-2) and telomerase inhibition. However, the targets of these alkaloid complexes are still unclear, though it is well-established that they demonstrate anticancer potency by interfering with multiple pathways of tumorigenesis and tumor progression both in vitro and in vivo. Over the last decade, many significant advances have been made towards the development of natural alkaloid-based metallo-drug therapeutics for intervention in cancer chemotherapy that have been summarized below and reviewed in this article.

Anti-cancer property and DNA binding interaction of first row transition metal complexes: A decade update

A review on metal complexes and its anti-cancer activities: Recent updates from in vivo studies

Metal Complexes with Aromatic N-Containing Ligands As Potential Agents in Cancer Treatment

Advances in anticancer alkaloid-derived metallo-chemotherapeutic agents in the last decade: Mechanism of action and future prospects

Metal-based Anticancer Chemotherapeutic Agents.

Homo and heterometallic ruthenium and platinum complexes with multiple targets for therapeutic applications: a review

Recent advances on the DNA interaction properties of Schiff bases and their metal complexes

Anticancer Metallocenes and Metal Complexes of Transition Elements from Groups 4 to 7

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials.

Applications of samarium complexes as cytotoxic, bioimaging and DNA interacting agents: a comprehensive review

Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity

Synthesis and Anti-Cancer Investigations of Copper(II) Complexes Based on Adenine

Toward Multi-Targeted Platinum and Ruthenium Drugs-A New Paradigm in Cancer Drug Treatment Regimens?

Interactions of Metal Ions with DNA, Its Constituents and Derivatives, which may be Relevant for Anticancer Research

Anticancer Activity of Metallodrugs and Metallizing Host Defense Peptides-Current Developments in Structure-Activity Relationship

A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs

Mononuclear Copper(II) Complexes with Polypyridyl Ligands: Synthesis, Characterization, DNA Interactions/Cleavages and in vitro Cytotoxicity towards Human Cancer Cells

Antitumor Activity of Pt(II), Ru(III) and Cu(II) Complexes

Bioactivity and Development of Small Non-Platinum Metal-Based Chemotherapeutics

Recently Reported Biological Activities and Action Targets of Pt(II)- and Cu(II)-Based Complexes

Synthesis and Investigations of the Antitumor Effects of First-Row Transition Metal(II) Complexes Supported by Two Fluorinated and Non-Fluorinated β-Diketonates